Allogene Craters To 52-Week Low On FDA Clinical Hold Of CAR-T Trials, Drags Peers As Well

The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc ALLO AlloCAR T trials in response to an abnormality that could theoretically cause cancer.

Related: Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma.

Here's what we know. A heavily pretreated lymphoma patient suffered a reduction in all blood cell lines after receiving an infusion of Allogene's anti-CD19 CAR-T candidate ALLO-501A. Analysis of the biopsy discovered anti-CD19 CAR-T cells with a chromosomal abnormality. The patient achieved a partial response to therapy.

The Company expects to provide additional updates in the coming weeks following consultation with the FDA. The FDA actively reviews the end of Phase 1 materials submitted in anticipation of an ALLO-501A pivotal Phase 2 trial.

Related: Allogene's Stock Jumps After Blood Cancer Candidates Show Durable Response.

Allogene's stock fell more than 30% in response to the news, affecting other companies too. Shares in Allogene's partner Cellectis SA CLLS, the biotech behind the TALEN gene-editing technology, fell almost 18%, and MaxCyte Inc MXCT also fell nearly 9%. In 2020, Allogene inked a licensing deal to develop allogeneic CAR-T therapies using MaxCyte's platform.

In contrast, shares in Autolus Therapeutics PLC AUTL rose 18% as investors re-evaluated its autologous CAR-Ts in light of the troubles of its off-the-shelf rival.

In reaction to the FDA hold, Goldman Sachs has downgraded Allogene from Buy to Neutral and slashed the price target from $71 to $20.

Related content: Benzinga's Full FDA Calendar.

Price Action: ALLO shares are down 38.4% at $15.02 during the premarket session on the last check Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsShort IdeasDowngradesHealth CarePrice TargetSmall CapFDAAnalyst RatingsMoversTrading IdeasGeneralCAR-TClinical HoldsPhase 1 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!